- Home
- IXHL vs ACRV Comparison
IXHL vs ACRV Comparison
Compare IXHL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- ACRV
- Stock Information
- Founded
- IXHL 2001
- ACRV 2018
- Country
- IXHL Australia
- ACRV United States
- Employees
- IXHL N/A
- ACRV N/A
- Industry
- IXHL
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- IXHL
- ACRV Health Care
- Exchange
- IXHL Nasdaq
- ACRV Nasdaq
- Market Cap
- IXHL 49.1M
- ACRV 47.8M
- IPO Year
- IXHL N/A
- ACRV 2022
- Fundamental
- Price
- IXHL $0.44
- ACRV $1.89
- Analyst Decision
- IXHL
- ACRV Buy
- Analyst Count
- IXHL 0
- ACRV 6
- Target Price
- IXHL N/A
- ACRV $17.75
- AVG Volume (30 Days)
- IXHL 36.4M
- ACRV 577.9K
- Earning Date
- IXHL 11-13-2025
- ACRV 11-12-2025
- Dividend Yield
- IXHL N/A
- ACRV N/A
- EPS Growth
- IXHL N/A
- ACRV N/A
- EPS
- IXHL N/A
- ACRV N/A
- Revenue
- IXHL $86,000.00
- ACRV N/A
- Revenue This Year
- IXHL $1,188.37
- ACRV N/A
- Revenue Next Year
- IXHL N/A
- ACRV $805.34
- P/E Ratio
- IXHL N/A
- ACRV N/A
- Revenue Growth
- IXHL 616.67
- ACRV N/A
- 52 Week Low
- IXHL $0.08
- ACRV $1.05
- 52 Week High
- IXHL $3.12
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- IXHL 41.95
- ACRV 69.76
- Support Level
- IXHL $0.43
- ACRV $1.77
- Resistance Level
- IXHL $0.50
- ACRV $1.99
- Average True Range (ATR)
- IXHL 0.07
- ACRV 0.12
- MACD
- IXHL -0.01
- ACRV 0.02
- Stochastic Oscillator
- IXHL 14.47
- ACRV 84.11
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.